O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-1.19%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$7.78B
AUM Growth
+$7.78B
(-14%)
Cap. Flow
-$241M
Cap. Flow
% of AUM
-3.1%
Top 10 Holdings %
Top 10 Hldgs %
29.03%
Holding
183
New
13
Increased
34
Reduced
44
Closed
24
Top Buys
| 1 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
$214M |
| 2 |
Pfizer
PFE
|
$154M |
| 3 |
Intuitive Surgical
ISRG
|
$84.1M |
| 4 |
Compass Therapeutics
CMPX
|
$68.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$66.3M |
Top Sells
| 1 |
Merck
MRK
|
$150M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$81.8M |
| 3 |
Elevance Health
ELV
|
$77.2M |
| 4 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$74.2M |
| 5 |
Progyny
PGNY
|
$71.1M |
Sector Composition
| 1 | Healthcare | 96.32% |
| 2 | Industrials | 0% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $374M | 4.8% | 6,028,307 | – | – |
|
2
Bristol-Myers Squibb
BMY
$96B
| $271M | 3.48% | 4,339,800 -175,600 | -4% | -$10.9M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $269M | 3.46% | 2,500,055 -110,300 | -4% | -$11.9M |
|
4
Boston Scientific
BSX
$156B
| $236M | 3.03% | 5,552,300 -281,300 | -5% | -$11.9M |
|
|
THRX
5
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $214M | 2.74% | +16,838,668 | New | +$214M |
|
6
Edgewise Therapeutics
EWTX
$1.51B
| $213M | 2.74% | 13,944,680 | – | – |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $209M | 2.69% | 1,426,400 +53,200 | +4% | +$7.8M |
|
8
PMV Pharmaceuticals
PMVP
$74.2M
| $169M | 2.18% | 7,330,423 | – | – |
|
|
9
Pfizer
PFE
$141B
| $154M | 1.99% | +2,615,400 | New | +$154M |
|
10
Humana
HUM
$36.5B
| $148M | 1.9% | 318,300 -16,700 | -5% | -$7.75M |
|
11
AbbVie
ABBV
$372B
| $145M | 1.86% | 1,068,800 -351,800 | -25% | -$47.6M |
|
12
Vertex Pharmaceuticals
VRTX
$100B
| $145M | 1.86% | 658,100 -219,300 | -25% | -$48.2M |
|
13
Edwards Lifesciences
EW
$47.8B
| $139M | 1.79% | 1,076,200 -50,200 | -4% | -$6.5M |
|
|
14
Merck
MRK
$210B
| $136M | 1.75% | 1,779,300 -1,953,100 | -52% | -$150M |
|
15
UnitedHealth
UNH
$281B
| $136M | 1.75% | 271,000 -118,700 | -30% | -$59.6M |
|
|
16
Intuitive Surgical
ISRG
$170B
| $134M | 1.73% | 373,800 +234,200 | +168% | +$84.1M |
|
17
Natera
NTRA
$23.1B
| $132M | 1.7% | 1,413,985 -158,815 | -10% | -$14.8M |
|
18
Adicet Bio
ACET
$59.9M
| $130M | 1.67% | 7,447,141 +214,285 | +3% | +$3.75M |
|
19
Arcutis Biotherapeutics
ARQT
$1.86B
| $126M | 1.62% | 6,073,850 | – | – |
|
20
Prelude Therapeutics
PRLD
$68.5M
| $125M | 1.61% | 10,039,691 | – | – |
|
21
Stryker
SYK
$150B
| $124M | 1.6% | 465,300 +127,900 | +38% | +$34.2M |
|
22
Guardant Health
GH
$8.41B
| $123M | 1.58% | 1,227,400 | – | – |
|
23
Iovance Biotherapeutics
IOVA
$807M
| $121M | 1.56% | 6,337,700 -307,400 | -5% | -$5.87M |
|
24
SPDR S&P Biotech ETF
XBI
$5.07B
| $113M | 1.45% | 1,009,700 -56,000 | -5% | -$6.27M |
|
|
SGEN
25
DELISTED
Seagen Inc. Common Stock
SGEN
| $101M | 1.3% | 655,600 +387,600 | +145% | +$59.9M |
|